Persistent Link:
http://hdl.handle.net/10150/613945
Title:
The Effect of Ipilimumab on the Endocrine Function
Author:
Qyra, Ollga; McBride, Ali
Affiliation:
College of Pharmacy, The University of Arizona
Issue Date:
2016
Rights:
Copyright © is held by the author.
Collection Information:
This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.
Publisher:
The University of Arizona.
Abstract:
Objectives: To test whether ipilimumab therapy affects the endocrine system in patients with Metastatic Melanoma. Methods: A retrospective chart review was performed that included patients with Metastatic Melanoma that had at least one dose of ipilimumab. Results: The primary finding of this study is that 38% of patients used at least 20 mg of prednisone daily or more while on Ipilimumab therapy. Only 33% of patients had endocrine lab values reported. Conclusions: There was not enough data collected to adequately show that Ipilimumab affects the endocrine system. There was also insufficient reporting of appropriate serum levels. More research on the importance of reporting lab values while on ipilimumab therapy needs to be conducted.
Description:
Class of 2016 Abstract
Keywords:
Ipilimumab; Endocrine; Metastatic Melanoma
Advisor:
McBride, Ali

Full metadata record

DC FieldValue Language
dc.contributor.advisorMcBride, Alien
dc.contributor.authorQyra, Ollgaen
dc.contributor.authorMcBride, Alien
dc.date.accessioned2016-06-21T20:30:41Z-
dc.date.available2016-06-21T20:30:41Z-
dc.date.issued2016-
dc.identifier.urihttp://hdl.handle.net/10150/613945-
dc.descriptionClass of 2016 Abstracten
dc.description.abstractObjectives: To test whether ipilimumab therapy affects the endocrine system in patients with Metastatic Melanoma. Methods: A retrospective chart review was performed that included patients with Metastatic Melanoma that had at least one dose of ipilimumab. Results: The primary finding of this study is that 38% of patients used at least 20 mg of prednisone daily or more while on Ipilimumab therapy. Only 33% of patients had endocrine lab values reported. Conclusions: There was not enough data collected to adequately show that Ipilimumab affects the endocrine system. There was also insufficient reporting of appropriate serum levels. More research on the importance of reporting lab values while on ipilimumab therapy needs to be conducted.en
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.subjectIpilimumaben
dc.subjectEndocrineen
dc.subjectMetastatic Melanomaen
dc.titleThe Effect of Ipilimumab on the Endocrine Functionen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.